
Concert Pharmaceuticals CNCE
Quarterly report 2022-Q3
added 11-07-2022
Concert Pharmaceuticals Depreciation & Amortization 2011-2026 | CNCE
Annual Depreciation & Amortization Concert Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.48 M | 1.6 M | 1.66 M | 1.25 M | 1.01 M | 893 K | 785 K | 1.05 M | 1.35 M | 1.45 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.66 M | 785 K | 1.25 M |
Quarterly Depreciation & Amortization Concert Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 941 K | - | 321 K | - | 1.15 M | - | 392 K | - | 1.21 M | 805 K | 408 K | - | 1.26 M | 849 K | 444 K | - | 875 K | 509 K | 253 K | - | 749 K | 493 K | 248 K | - | 655 K | 430 K | 210 K | - | 577 K | 368 K | 183 K | - | 982 K | 650 K | 326 K | - | 1.01 M | 672 K | 338 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.26 M | 183 K | 618 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Aptorum Group Limited
APM
|
1.13 M | $ 0.88 | - | $ 6.47 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.56 | -0.49 % | $ 3.74 B | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
487 K | - | 17.91 % | $ 11.1 M | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
199 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
Aquestive Therapeutics
AQST
|
548 K | $ 4.1 | 0.12 % | $ 438 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 23.01 | -1.2 % | $ 2.93 B | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.43 | -3.38 % | $ 381 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 2.99 | 2.75 % | $ 4.92 M | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
bluebird bio
BLUE
|
28 M | - | - | $ 546 M | ||
|
Cara Therapeutics
CARA
|
95 K | - | -3.03 % | $ 260 M | ||
|
CASI Pharmaceuticals
CASI
|
468 K | - | - | $ 35.4 M | ||
|
BioXcel Therapeutics
BTAI
|
300 K | $ 1.04 | -1.56 % | $ 12.7 M | ||
|
ChemoCentryx
CCXI
|
3.14 M | - | - | $ 3.74 B | ||
|
Cabaletta Bio
CABA
|
1.65 M | $ 2.82 | -1.4 % | $ 283 M | ||
|
Cidara Therapeutics
CDTX
|
154 K | - | - | $ 1.41 B |